000045946 000__ 00956cam\a22003855i\4500
000045946 001__ 45946
000045946 003__ SzGeWIPO
000045946 005__ 20240708150221.0
000045946 006__ m\\\\eo\\d\\\\\\\\
000045946 007__ cr bn |||m|||a
000045946 008__ 220429s2022\\\\sz\\\\\\o\\\\\000\0\eng\d
000045946 022__ $$aOnline: 2045-9815
000045946 0247_ $$a10.4337/qmjip.2022.01.06$$2doi
000045946 035__ $$a(OCoLC)1296156375
000045946 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000045946 041__ $$aeng
000045946 1001_ $$aHan, Weiwei.
000045946 24500 $$aSupplemental experimental data in Chinese pharmaceutical patent practice:$$bacceptable or not? /
000045946 260__ $$aEdward Elgar Publishing Ltd.$$c2022
000045946 300__ $$a1 online resource 110-134 pages)
000045946 336__ $$atext$$2rdacontent
000045946 337__ $$acomputer$$2rdamedia
000045946 338__ $$aonline resource$$bcr$$2rdacarrier
000045946 4901_ $$aQueen Mary Journal Of Intellectual Property ;$$v12, 1, 2022, pp. 110-134.
000045946 588__ $$aCrossref
000045946 590__ $$aPublished online: 28-Feb-22
000045946 650_4 $$aHealth Industry.
000045946 650_4 $$aPharmaceuticals.
000045946 7730_ $$tQueen Mary Journal of Intellectual Property$$wQMJ
000045946 830_0 $$aQueen Mary Journal Of Intellectual Property ;$$v12, 1, 2022, pp. 110-134.
000045946 85641 $$uhttps://www.elgaronline.com/view/journals/qmjip/12-1/qmjip.2022.01.06.xml$$yOnline version
000045946 904__ $$aJournal article
000045946 980__ $$aQMJ